NexImmune, Inc. (Nasdaq: NEXI), a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells, today announced that Scott Carmer, Chief Executive Officer, will present a company overview at the virtual 2021 Barclays Global Healthcare Conference on Thursday, March 11, 2021 at 10:55 a.m. Eastern time.
The presentation will be accessible via live webcast by visiting https://ir.neximmune.com/investors/events-and-presentations. A replay will be available on the NexImmune website following the presentation.
About NexImmune
NexImmune, based in Gaithersburg, Maryland, is a clinical-stage biotechnology company developing a novel approach to immunotherapy designed to orchestrate a targeted immune response by directing the function of antigen-specific T cells to generate a specific, potent and durable immune response that mimics natural biology. For more information, visit www.neximmune.com.
Contacts
Investors:
Chad Rubin
Solebury Trout
646-378-2947
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
Mike Beyer
Sam Brown Inc. Healthcare Communications
312-961-2502
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$0.00 |
| Daily Volume: | 0 |
February 06, 2024 February 02, 2024 October 19, 2023 August 10, 2023 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
